AU469986B2 - Sulfobenzylpenicillin salts - Google Patents

Sulfobenzylpenicillin salts

Info

Publication number
AU469986B2
AU469986B2 AU57600/73A AU5760073A AU469986B2 AU 469986 B2 AU469986 B2 AU 469986B2 AU 57600/73 A AU57600/73 A AU 57600/73A AU 5760073 A AU5760073 A AU 5760073A AU 469986 B2 AU469986 B2 AU 469986B2
Authority
AU
Australia
Prior art keywords
sulfobenzylpenicillin
salts
sulfobenzylpenicillin salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU57600/73A
Other languages
English (en)
Other versions
AU5760073A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU5760073A publication Critical patent/AU5760073A/en
Application granted granted Critical
Publication of AU469986B2 publication Critical patent/AU469986B2/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU57600/73A 1972-07-01 1973-07-02 Sulfobenzylpenicillin salts Expired AU469986B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP66301/72 1972-07-01
JP6630172A JPS5512435B2 (ref) 1972-07-01 1972-07-01

Publications (2)

Publication Number Publication Date
AU5760073A AU5760073A (en) 1975-01-09
AU469986B2 true AU469986B2 (en) 1976-02-26

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57600/73A Expired AU469986B2 (en) 1972-07-01 1973-07-02 Sulfobenzylpenicillin salts

Country Status (15)

Country Link
US (1) US3925357A (ref)
JP (1) JPS5512435B2 (ref)
AT (1) AT325206B (ref)
AU (1) AU469986B2 (ref)
BE (1) BE801588A (ref)
CA (1) CA996548A (ref)
CH (1) CH573435A5 (ref)
CS (1) CS168036B2 (ref)
DE (1) DE2332840A1 (ref)
FR (1) FR2190414B1 (ref)
GB (1) GB1386566A (ref)
HU (1) HU166029B (ref)
NL (1) NL7308048A (ref)
PL (1) PL92969B1 (ref)
SE (1) SE402916B (ref)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (ref) * 1978-07-29 1980-02-13
EE05735B1 (et) * 2001-02-24 2015-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (ref) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
CA996548A (en) 1976-09-07
DE2332840A1 (de) 1974-01-17
CS168036B2 (ref) 1976-05-28
FR2190414A1 (ref) 1974-02-01
HU166029B (ref) 1974-12-28
CH573435A5 (ref) 1976-03-15
US3925357A (en) 1975-12-09
AU5760073A (en) 1975-01-09
PL92969B1 (ref) 1977-04-30
GB1386566A (en) 1975-03-12
JPS5512435B2 (ref) 1980-04-02
NL7308048A (ref) 1974-01-03
BE801588A (fr) 1973-12-28
FR2190414B1 (ref) 1976-07-02
AT325206B (de) 1975-10-10
SE402916B (sv) 1978-07-24
JPS4925121A (ref) 1974-03-06

Similar Documents

Publication Publication Date Title
AU469986B2 (en) Sulfobenzylpenicillin salts
AU470375B2 (en) Substituted w-pentanorprostaglandins
AU5996573A (en) Pyridinium salts
CA980352A (en) Substituted aminohalopyridines
CA950831A (en) Biocidal salts
CA995666A (en) 1-amino-pyridinium salts
AU475748B2 (en) Napnthopyrans
CA1021783A (en) Sulphamoylphenyl-imidazolidinones
CA991638A (en) Substituted 3-cyanobenzenesulfonamides
CA1010049A (en) N-acyl-o-hydrocarbylphosphoroamidothioate salts
AU472956B2 (en) Substituted benzodioxoles
CA1007639A (en) Unsymmetrically-substituted-s-triazines
CA1017752A (en) 1-substituted-3-amino-pyrazol-5-ones
AU471369B2 (en) Diphenylmethoxyethylamines
AU5644273A (en) Halocyclopropranes
CA995680A (en) Substituted 2-benzoyloxazolidines
CA1026349A (en) 2-aminoalkyl-3-phenyl-indoles
AU5644173A (en) Halocyclopropanes
CA893696A (en) Amcyclodin salts
CA907019A (en) N-tritylimidazolium salts
CA913109A (en) Thienyliodonium salts
AU491554B1 (en) Pyridinium salts
CA1007648A (en) Plicatamides
AU472554B2 (en) Isothocyanobenzoxazoles
CA893124A (en) Substituted 2-azabicycloalkanes